Arovella Therapeutics Ltd (ASX:ALA) has added an industry veteran to its board of non-executive directors with the appointment of Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips.
Phillips boasts more than 30 years’ operational management experience in the industry across Europe, Asia, and Australia.
As CEO and managing director of Pharmaxis, Phillips oversaw a company restructure focused on building value, forging new partnerships, and fostering the development of the company’s product pipeline.
Phillips holds a Bachelor of Pharmacy Honours degree from Nottingham University in the U.K. and an MBA from Henley Management College, UK. Phillips is also a graduate of the Australian Institute of Company Directors (GAICD).
“Incredible breadth of experience”
“Gary has an incredible breadth of experience across the drug development continuum, from early-stage research to the creation of significant value-creating partnerships,” Arovella Therapeutics CEO and managing director Dr Michael Baker said.
“We welcome Gary’s experience across numerous domains, and we are delighted that Gary will play an important part in Arovella’s next phase.”
Arovella’s two area of focus are oncology and conditions that impact the central nervous system.
Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers, while also developing its DKK1-peptide targeting technology licenced from MD Anderson to be used in conjunction with its iNKT cell therapy platform.
“Arovella has achieved a great deal over the past twelve months,” Gray Phillips said.
“I am looking forward to bringing my expertise to the board and assisting the company as it progresses its technologies into clinical development and beyond.”